ABSTRACT
Organ transplantation has revolutionised the management of solid organ failure such as end-stage liver disease with good long-term patient and graft survivals. The major source of morbidity and mortality is related to over-or underimmunosuppression. Newer developments and refinements in immunosuppressive agents have led to better overall care and outcomes following allograft transplantation. However, the elusive complexities of the body’s immune response continue to pose formidable challenges.
